Chronic Myelogenous Leukemia (CML): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm universally defined by the Philadelphia chromosome (Ph) — the t(9;22)(q34;q11.2) reciprocal translocation creating the BCR-ABL1 fusion oncogene encoding a constitutively active tyrosine kinase. CML comprises approximately 15% of adult leukemias in Western countries, with approximately 9,000 new US cases per year. Three clinical phases: chronic phase (CML-CP, present in approximately 85% of patients at diagnosis), accelerated phase (CML-AP), and blast crisis (CML-BC, resembling acute leukemia). The discovery of imatinib mesylate (Gleevec) in 1996 and its clinical introduction in 2001 represents one of the most transformative events in oncology: CML-CP patients treated with TKI now have a 10-year overall survival exceeding 85-90%, approaching that of the general age-matched population — a landmark achievement of molecular targeted oncology.

The BCR-ABL1 fusion gene created by the Philadelphia chromosome translocation is the singular defining molecular driver of CML; without it, CML does not exist. The translocation arises as an acquired somatic mutation in a hematopoietic stem cell, leading to clonal expansion of BCR-ABL1-positive myeloid progenitors. BCR-ABL1 constitutively activates downstream signaling through JAK/STAT, PI3K/AKT, and RAS/MAPK pathways, inhibiting apoptosis and promoting cell proliferation. High-dose ionizing radiation (as demonstrated in atomic bomb survivors of Hiroshima and Nagasaki) is the only confirmed environmental risk factor for CML, substantially increasing incidence. Routine diagnostic radiation (CT scans, X-rays) has not been associated with CML risk. No hereditary predisposition, familial clustering, dietary, or lifestyle factors are established as causative for CML. Male sex confers a slight increased risk (approximately 1.4:1 male-to-female ratio).

Chronic phase CML: approximately 40-50% of patients are entirely asymptomatic at diagnosis, with disease identified incidentally from a routine complete blood count showing marked leukocytosis. When symptomatic, CML-CP presents with: progressive fatigue, pallor, and exercise intolerance from anemia; symptomatic splenomegaly — left upper quadrant fullness, dragging discomfort, and early satiety from massive splenic enlargement; drenching night sweats and low-grade fever; unexplained weight loss; and rarely, hyperleukocytosis symptoms (respiratory distress, priapism, visual changes) when WBC exceeds 300-400×10⁹/L. Blast phase: presents like acute leukemia with severe pancytopenia, opportunistic infections, bleeding, and multi-organ infiltration — fever, bone pain, lymphadenopathy, and clinical deterioration. WBC at diagnosis may exceed 100-200×10⁹/L in symptomatic chronic-phase patients.

Peripheral blood smear: marked leukocytosis with the complete spectrum of myeloid maturation (myelocytes, metamyelocytes, neutrophils, eosinophilia, basophilia — basophilia is characteristic); thrombocytosis is common; anemia in advanced disease. Philadelphia chromosome confirmed by standard karyotyping (G-banding) or FISH on bone marrow. BCR-ABL1 RT-PCR (quantitative PCR on peripheral blood, expressed on the International Scale [IS]) is the gold standard for diagnosis and molecular response monitoring; sensitivity to MR4.5 (0.0032% IS). Bone marrow biopsy assesses phase (CP vs AP vs BC), fibrosis, and cytogenetic evolution. ABL1 kinase domain mutation analysis is performed at treatment failure or suboptimal response. ELN 2020 response milestones: BCR-ABL1 ≤10% IS at 3 months (early molecular response, EMR), ≤1% IS at 6 months (major molecular response, MMR), ≤0.1% IS at 12 months; deviations prompt mutation analysis and treatment change.

First-line TKI therapy is chosen based on risk (Sokal or EUTOS score), comorbidities, and TFR aspirations. Imatinib 400 mg daily (first-generation, excellent safety profile, lower cost, effective for low-risk disease, achieves TFR in approximately 40% of deep responders). Dasatinib 100 mg daily or nilotinib 300 mg BD (second-generation, achieve faster and deeper molecular responses at 12 months, preferred for high-risk or intermediate-risk CML, higher TFR rates). Bosutinib 400 mg daily (second-generation, favorable for patients with cardiovascular risk contraindicating dasatinib or nilotinib). Third-line: ponatinib 45 mg daily for T315I 'gatekeeper' mutation (resistant to all first- and second-generation TKIs) or after two TKI failures; cardiovascular monitoring required. Asciminib (Scemblix) — first-in-class STAMP inhibitor targeting the BCR-ABL1 myristoyl pocket — FDA-approved for CML-CP after ≥2 prior TKIs or for T315I-mutated CML; achieves 25% MMR rate in heavily pretreated patients. Treatment-free remission (TFR): TKI may be discontinued after ≥3 years of stable MR4.5 in selected patients. Blast phase: intensive AML-like chemotherapy plus TKI bridging to allogeneic SCT.

Prognosis for CML-CP treated with tyrosine kinase inhibitors has been transformed: patients diagnosed today have expected survival approaching that of the age-matched general population. Ten-year OS for CML-CP treated with imatinib exceeds 85-90% (IRIS trial long-term follow-up). Second-generation TKIs (dasatinib, nilotinib) achieve superior 5-year major molecular response rates compared to imatinib and potentially longer PFS, though overall survival benefit versus imatinib has not been definitively confirmed. Treatment-free remission (TFR) — sustained deep molecular response after TKI discontinuation — is achieved in approximately 40-50% of patients who attain MR4.5 for at least 2 years, representing a meaningful quality-of-life endpoint. Blast-phase CML (CML-BC) carries a markedly worse prognosis: with TKI plus intensive chemotherapy bridging to allogeneic SCT, median OS is 6-12 months for myeloid BC and slightly better (12-18 months) for lymphoid BC. Allogeneic SCT for blast phase achieves 5-year OS of approximately 25-35% in eligible patients. Key prognostic factors include Sokal and EUTOS risk scores at diagnosis, achievement of ELN 2020 response milestones (BCR-ABL1 at or below 10% IS at 3 months is the most predictive milestone), ABL1 kinase domain mutation status at TKI failure, and disease phase at treatment initiation. Patients who fail EMR at 3 months have significantly worse long-term outcomes and require ABL1 mutation testing and TKI switch. Long-term monitoring requires BCR-ABL1 quantitative PCR every 3 months for the first year, then every 3-6 months; patients in TFR require monthly PCR monitoring for 12 months to detect molecular relapse promptly before clinical progression.

CML cannot be prevented by any established lifestyle or dietary measure. The only confirmed environmental risk factor — high-dose ionizing radiation — should be minimized through occupational radiation safety protocols, and unnecessary high-dose therapeutic radiation avoided. Medical ionizing radiation (diagnostic CT scans, radiotherapy for other malignancies) should be prescribed at the lowest effective dose. Because CML arises from an acquired sporadic somatic mutation in the BCR-ABL1 kinase, it is not hereditary and does not require genetic screening of family members. Early detection through annual health check including CBC enables diagnosis of CML in chronic phase — before progression to blast crisis — when outcomes with TKI therapy are excellent. CML diagnosed in blast phase has a substantially worse prognosis; routine CBC in adults over age 40 may identify incidental leukocytosis warranting investigation for CML. Ongoing pharmacovigilance during TKI therapy prevents blast phase transformation by maintaining molecular control.

See a physician promptly for: an unexplained finding of leukocytosis (white cell count above 15-20×10⁹/L) on a blood test — routine CBC is the most common way CML is first identified; left upper quadrant fullness, early satiety, or palpable splenomegaly; progressive fatigue, pallor, or unexplained weight loss; night sweats not explained by infection or other obvious cause; or hyperleukocytosis symptoms (breathlessness, visual changes, priapism) which may indicate leukostasis requiring emergency treatment. Established CML patients on TKI therapy must attend scheduled BCR-ABL1 quantitative PCR monitoring every 3 months in the first year, then every 3-6 months — molecular monitoring is the cornerstone of safe CML management and enables early detection of resistance or suboptimal response. Patients in TFR who have discontinued TKI must undergo monthly PCR monitoring for the first 12 months to detect molecular relapse promptly so TKI can be restarted before clinical progression.